Patents by Inventor Carl Richard Torstenson

Carl Richard Torstenson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SEMAGLUTIDE FOR USE IN MEDICINE
    Publication number: 20240075106
    Abstract: The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of non-alcoholic steatohepatitis.
    Type: Application
    Filed: October 24, 2023
    Publication date: March 7, 2024
    Inventors: Morten Hansen, Martin Linder, Carl Richard Torstenson, Mads Sundby Palle, Lars Holm Damgaard
  • SEMAGLUTIDE FOR USE IN MEDICINE
    Publication number: 20230023012
    Abstract: The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of non-alcoholic steatohepatitis.
    Type: Application
    Filed: September 20, 2022
    Publication date: January 26, 2023
    Inventors: Morten Hansen, Martin Linder, Carl Richard Torstenson, Mads Sundby Palle, Lars Holm Damgaard
  • Semaglutide for use in medicine
    Patent number: 11478533
    Abstract: The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of non-alcoholic steatohepatitis.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: October 25, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Morten Hansen, Martin Linder, Carl Richard Torstenson, Mads Sundby Palle, Lars Holm Damgaard